Subscribe To
OPNT / Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript
Content Topics
Opiant
Pharmaceuticals
Inc
OPNT
Roger
Crystal
2022
Pharmaceuticals
opnt
Results
Earnings
Transcript
Stock
OPNT News
By Seeking Alpha
February 11, 2023
What's The Opiant CVR Worth?
Opiant appears on track to be acquired for $20/share and offers various Contingent Value Rights (CVRs) linked to a potential drug launch. The drug hel more_horizontal
By Seeking Alpha
January 13, 2023
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
I love to get a CVR during a takeover process. This happens a lot when pharma or biotech companies with important unapproved assets get bought. more_horizontal
By InvestorPlace
November 14, 2022
Why Is Opiant Pharma (OPNT) Stock Up 116% Today?
Opiant Pharmaceuticals (NASDAQ: OPNT ) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is off more_horizontal
By Seeking Alpha
May 14, 2022
Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q1 2022 Results Conference Call May 10, 2022 4:30 PM ET Company Participants Ben Atkins - Vice President, more_horizontal
By Benzinga
April 28, 2022
Why Opiant Pharmaceuticals Shares Are Soaring Today
Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced topline results from a pharmacodynamic (PD) study for OPNT003, nasal nalmefene for opioid overd more_horizontal
By Benzinga
January 25, 2022
Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program
The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmace more_horizontal
By Benzinga
January 25, 2022
Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program
The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmace more_horizontal
By Benzinga
January 25, 2022
Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program
The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmace more_horizontal